May 27, 2020
Bayer Yakuhin on May 26 launched Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). In the PIII ARAMIS trial, the drug plus androgen deprivation therapy (ADT) delivered a median metastasis-free survival (MFS) of 40.4 months, showing a...read more